Osimertinib Plus Chemotherapy Offers Overall Survival Advantage For Patients With Egfr-mutated Advanced Nsclc

Final wide endurance (OS) results from nan Phase III FLAURA2 proceedings show that first-line osimertinib positive chemotherapy importantly improves OS compared to osimertinib monotherapy successful patients pinch EGFR-mutated (EGFRm) precocious non-small compartment lung crab (NSCLC).

These findings, presented coming astatine nan International Association for nan Study of Lung Cancer (IASLC) 2025 World Conference connected Lung Cancer, support osimertinib positive chemotherapy arsenic a caller standard-of-care curen action successful this diligent population, according to David Planchard, MD, PhD, Department of Medical Oncology, Institut Gustave Roussy, Thoracic Unit.

Osimertinib, a third-generation, CNS-active EGFR tyrosine kinase inhibitor (EGFR-TKI), is presently a preferred first-line curen for EGFRm precocious NSCLC. The global, open-label, randomized Phase III FLAURA2 study (NCT04035486) evaluated whether adding chemotherapy (pemetrexed pinch cisplatin aliases carboplatin) to osimertinib could supply further endurance benefit.

A full of 557 patients pinch antecedently untreated, EGFRm (Ex19del/L858R) locally precocious aliases metastatic NSCLC were randomized 1:1 to person osimertinib positive chemotherapy (n=279) aliases osimertinib monotherapy (n=278). The superior endpoint was progression-free endurance (PFS), pinch OS arsenic a cardinal secondary endpoint. Patients were eligible if they had a WHO capacity position of 0 aliases 1, and unchangeable CNS metastases were permitted.

At a median follow-up of astir 57% maturity, osimertinib positive chemotherapy demonstrated a statistically important and clinically meaningful betterment successful OS versus osimertinib monotherapy (HR 0.77; 95% CI 0.61–0.96; p=0.02). Median OS was 47.5 months pinch operation therapy versus 37.6 months pinch monotherapy. The 36-month endurance complaint was 63% versus 51%, respectively. The OS use was accordant crossed predefined subgroups.

The information floor plan of nan operation was manageable and accordant pinch nan known profiles of nan individual treatments. No caller information signals emerged pinch longer follow-up. Adverse events (AEs) starring to discontinuation of osimertinib occurred successful 12% of patients successful nan operation limb versus 7% successful nan monotherapy arm.

These compelling wide endurance results corroborate osimertinib positive chemotherapy arsenic a first-line modular of attraction for patients pinch EGFR-mutated precocious NSCLC. By combining osimertinib pinch chemotherapy, we are capable to widen endurance for these patients while maintaining a manageable information profile."

Dr. David Planchard, MD, PhD, Department of Medical Oncology, Institut Gustave Roussy, Thoracic Unit

The FLAURA2 proceedings results reenforce osimertinib arsenic nan backbone therapy successful this setting, pinch nan summation of chemotherapy offering a meaningful OS advantage for patients pinch EGFRm precocious NSCLC, he said.